GC-197 is under clinical development by Gracell Biotechnologies and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GC-197’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GC-197 is under development for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia and B lymphoblastic lymphoma. The therapeutic candidate comprises of allogeneic T-cells are genetically engineered to express chimeric antigen receptor (CAR) that targets cells expressing CD-19 and CD7. These T-cells are edited by CRISPR to eliminate expression of endogenous T-cell receptor (TCR). The therapeutic candidate is being developed based on TruUCAR technology. It is administered by intravenous route.
Gracell Biotechnologies overview
Gracell Biotechnology Shanghai Co Ltd operates as a biopharmaceutical company. The Company develops cellular therapeutics and other biotechnology. The company is headquartered in China.
For a complete picture of GC-197’s drug-specific PTSR and LoA scores, buy the report here.